Stockholders of 89bio will be compensated with a sum of up to $20.50 for each share they hold. This amount includes $14.50 per share in cash upon completion of the deal, along with a non-tradable contingent value right (CVR) for a potential additional $6.00 per share in cash. The transaction is valued at a total equity value of around $3.5 billion.